Company Overview of Daiichi Sankyo Europe GmbH
Daiichi Sankyo Europe GmbH develops, manufactures, and markets pharmaceutical products for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders. The company also provides products for cardiovascular and thromboembolic diseases, as well as antiplatelet agents. Its products include LIXIANA for anticoagulation; Efient for acute coronary syndrome requiring percutaneous coronary intervention; and Olmetec, Olmetec Plus, Sevikar, and Sevikar HCT for essential hypertension. The company offers its products in Germany and internationally. Daiichi Sankyo Europe GmbH was formerly known as Sankyo Pharma GmbH and changed its name to Daiichi Sankyo Europe GmbH in July 2006. The compan...
Founded in 1910
Key Executives for Daiichi Sankyo Europe GmbH
Chairman of the Board, Chief Executive Officer and Managing Director
CEO & MD of Daiichi Sankyo Austria, CEO & MD of Deutschland and CEO & MD of (Schweiz) AG
President of Daiichi Sankyo France SAS
Compensation as of Fiscal Year 2017.
Daiichi Sankyo Europe GmbH Key Developments
Daiichi Sankyo Europe GmbH Initiates ENVISAGE-TAVI AF Study Investigating
Apr 27 17
Daiichi Sankyo Europe GmbH announced that the first patient has been enrolled into the ENVISAGE-TAVI AF study. The multinational, randomised phase 3b study will evaluate a treatment regimen based on the company's oral, once-daily direct factor Xa-inhibitor edoxaban (known by the brand name LIXIANA outside the US and SAVAYSA in the US) against a vitamin K antagonist based regimen, with or without antiplatelet therapy, in patients with atrial fibrillation (AF) following successful transcatheter aortic valve implantation (TAVI). The study will investigate the incidence of net adverse clinical events (NACE), including the composite of all-cause death, myocardial infarction (MI), ischaemic stroke, systemic thromboembolism (SEE), valve thrombosis, and major bleeding (International Society on Thrombosis and Haemostasis [ISTH] definition). Approximately 1,400 patients will be enrolled in ENVISAGE-TAVI AF from 200 clinical sites across Europe, the United States and Canada.
Daiichi Sankyo Europe GmbH Presents at The 14th Annual BIO Asia International Conference, Mar-15-2017 10:30 AM
Mar 11 17
Daiichi Sankyo Europe GmbH Presents at The 14th Annual BIO Asia International Conference, Mar-15-2017 10:30 AM. Venue: Grand Hyatt Tokyo, Tokyo, Japan.
Daiichi Sankyo Europe GmbH Announces Initiation of Real-World Study in LIXIANA (Edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in Non-Valvular Atrial Fibrillation and Venous Thromboembolism
Dec 8 16
Daiichi Sankyo Europe GmbH (Daiichi Sankyo) announced that the first patient has been enrolled in the EMIT-AF/VTE (Edoxaban Management In diagnostic and Therapeutic procedures) study. This registry will collect real-world clinical data on the use of once-daily LIXIANA® (edoxaban) with regard to diagnostic and interventional procedures in patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE). Limited information is currently available regarding the use of edoxaban in patients undergoing medical procedures. Patients who are treated with non-vitamin K antagonist oral anticoagulants (NOACs), such as edoxaban, undergo diagnostic and therapeutic procedures at a rate of 10% a year, and if the surgical interventions carry a bleeding risk, NOAC treatment must be temporarily discontinued. The EMIT-AF/VTE study will provide further insight into the use of edoxaban in patients undergoing diagnostic and therapeutic procedures. Patients will be enrolled from primary and secondary care settings, as well as other specialty settings. The primary objective of the study is to document the peri-procedural management of edoxaban and collect data on safety and other outcomes in these patients. The primary safety outcome is the rate of major bleeding (within 30 days post intervention) using the ISTH definition. The EMIT-AF/VTE registry will comprise approximately 2,000 patients over the next two and a half years. Data will be collected from patients treated with edoxaban for 2,000 planned or unplanned procedures across 500 sites, including hospitals and office-based sites, in Belgium, France, Germany, Italy, The Netherlands, Spain, and the UK. Daiichi Sankyo is also reviewing options to expand the EMIT-AF/VTE registry to clinical sites beyond Europe.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|